Nan Fung-backed mitochondrial therapy developer Stealth BioTherapeutics floated at the foot of its range to raise $78m, having disclosed $100m in financing last June.

Stealth BioTherapeutics, a US-based mitochondrial dysfunction drug developer that counts an affiliate of property development conglomerate as an investor, has floated in a $78m initial public offering. The offering consisted of 6.5 million American Depositary Shares (ADSs), each of which represent 12 ordinary shares, priced at $12.00 each, at the bottom of its $12 to…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.